Form 4: Serina Therapeutics CSO Sells Shares After Option Exercise

Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, sold a total of 6,500 common shares in early December 2025 after exercising stock options, pursuant to a Rule 10b5-1 plan.

Summary

• Randall Moreadith, Chief Scientific Officer of Serina Therapeutics, Inc. (SER), reported transactions involving the company's common stock.
• On December 2, 2025, Moreadith exercised options to acquire 1,500 shares of common stock at an exercise price of $0.06 per share.
• Immediately following the exercise on December 2, 2025, Moreadith sold these 1,500 shares at a weighted average price of $3.9052 per share.
• On December 3, 2025, Moreadith exercised options to acquire 5,000 shares of common stock at an exercise price of $0.06 per share.
• Immediately following the exercise on December 3, 2025, Moreadith sold these 5,000 shares at a weighted average price of $3.5246 per share.
• All reported transactions were made pursuant to a Rule 10b5-1(c) plan, indicating they were pre-scheduled.
• Following these transactions, Moreadith's direct beneficial ownership of common stock from these specific transactions is 0 shares.
• The number of stock options (right to buy) beneficially owned decreased from 376,686 to 371,686.

Sentiment

Score: 5

Explanation: The transactions represent routine insider activity, specifically the exercise of vested options and immediate sale of shares, which is common for executive compensation. The presence of a Rule 10b5-1 plan mitigates any negative sentiment typically associated with insider selling, making the overall sentiment neutral.

Positives

• The sale prices ($3.9052 and $3.5246) are significantly higher than the exercise price ($0.06), indicating a substantial profit for the insider on these specific transactions.
• The transactions were conducted under a Rule 10b5-1(c) plan, which suggests the sales were pre-scheduled and not based on immediate, non-public information.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces the insider's direct equity stake.

Risks

• Market perception risk: While planned, insider selling can sometimes lead to negative market sentiment or speculation about the company's future prospects.

Future Outlook

NA

Industry Context

NA

Corporate Governance

Stakeholder Impact

• Shareholders may observe the reduction in direct equity stake by a key executive, which could lead to varied interpretations, though the 10b5-1 plan typically lessens concerns.

Key Dates

Recommendation

While the filing reports insider selling, the transactions were executed under a pre-arranged Rule 10b5-1 plan. This suggests the sales are part of a routine liquidity or diversification strategy rather than a signal of a negative outlook on the company's future. Therefore, this Form 4 alone does not provide sufficient new information to warrant a change from a 'hold' position, but investors should monitor future insider activity and broader company performance.

Keywords

Serina Therapeutics, SER, Form 4, insider trading, stock options, share sale, Randall Moreadith, Chief Scientific Officer, 10b5-1 plan